Cargando…
LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128249/ https://www.ncbi.nlm.nih.gov/pubmed/34012913 http://dx.doi.org/10.3389/fonc.2021.630300 |
_version_ | 1783694083758227456 |
---|---|
author | Guo, Wenhui Li, Jingyi Huang, Haobo Fu, Fangmeng Lin, Yuxiang Wang, Chuan |
author_facet | Guo, Wenhui Li, Jingyi Huang, Haobo Fu, Fangmeng Lin, Yuxiang Wang, Chuan |
author_sort | Guo, Wenhui |
collection | PubMed |
description | Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the poor survival of patients with triple negative breast cancer (TNBC) tissues. Lnc-PCIR overexpression significantly promoted cell proliferation, migration, and invasion in vitro and in vivo. RNA pulldown, RNA immunoprecipitation (RIP) and RNA transcriptome sequencing technology (RNA-seq) was performed to identify the associated proteins and related signaling pathways. Mechanistically, higher Lnc-PCIR level of blocks PABPC4 proteasome-dependent ubiquitination degradation; stable and highly expressed PABPC4 can further increase the stability of TAB3 mRNA, meanwhile, overexpression of Lnc-PCIR can disrupt the binding status of TAB3 and TAB2 which lead to activate the TNF-α/NF-κB pathway in TNBC cells. Our findings suggest that Lnc-PCIR promotes tumor growth and metastasis via up-regulating the mRNA/protein level of TAB3 and PABPC4, activating TNF-α/NF-κB signaling pathway in TNBC. |
format | Online Article Text |
id | pubmed-8128249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81282492021-05-18 LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer Guo, Wenhui Li, Jingyi Huang, Haobo Fu, Fangmeng Lin, Yuxiang Wang, Chuan Front Oncol Oncology Long non-coding RNAs (LncRNA) as the key regulators in all stages of tumorigenesis and metastasis. However, the underlying mechanisms are largely unknown. Here, we report a lncRNA RP11-214F16.8, which renamed Lnc-PCIR, is upregulated and higher RNA level of Lnc-PCIR was positively correlated to the poor survival of patients with triple negative breast cancer (TNBC) tissues. Lnc-PCIR overexpression significantly promoted cell proliferation, migration, and invasion in vitro and in vivo. RNA pulldown, RNA immunoprecipitation (RIP) and RNA transcriptome sequencing technology (RNA-seq) was performed to identify the associated proteins and related signaling pathways. Mechanistically, higher Lnc-PCIR level of blocks PABPC4 proteasome-dependent ubiquitination degradation; stable and highly expressed PABPC4 can further increase the stability of TAB3 mRNA, meanwhile, overexpression of Lnc-PCIR can disrupt the binding status of TAB3 and TAB2 which lead to activate the TNF-α/NF-κB pathway in TNBC cells. Our findings suggest that Lnc-PCIR promotes tumor growth and metastasis via up-regulating the mRNA/protein level of TAB3 and PABPC4, activating TNF-α/NF-κB signaling pathway in TNBC. Frontiers Media S.A. 2021-05-03 /pmc/articles/PMC8128249/ /pubmed/34012913 http://dx.doi.org/10.3389/fonc.2021.630300 Text en Copyright © 2021 Guo, Li, Huang, Fu, Lin and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Guo, Wenhui Li, Jingyi Huang, Haobo Fu, Fangmeng Lin, Yuxiang Wang, Chuan LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title | LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title_full | LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title_fullStr | LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title_full_unstemmed | LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title_short | LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer |
title_sort | lncrna pcir is an oncogenic driver via strengthen the binding of tab3 and pabpc4 in triple negative breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128249/ https://www.ncbi.nlm.nih.gov/pubmed/34012913 http://dx.doi.org/10.3389/fonc.2021.630300 |
work_keys_str_mv | AT guowenhui lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer AT lijingyi lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer AT huanghaobo lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer AT fufangmeng lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer AT linyuxiang lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer AT wangchuan lncrnapcirisanoncogenicdriverviastrengthenthebindingoftab3andpabpc4intriplenegativebreastcancer |